An inorganic molecule is a psychoactive substance whose molecular structure lacks the carbon–hydrogen backbone that defines organic chemistry. The grouping is strictly structural — a chemical classification, not a pharmacological one — and its members share no receptor target, no clinical indication, and no characteristic experience.
The class is small and chemically heterogeneous. Lithium is an elemental alkali-metal cation administered as a carbonate or citrate salt; nitrous oxide is a simple three-atom inorganic gas (N2O). Their only commonality is the absence of an organic scaffold, and the class therefore reads as a structural boundary case rather than a unified pharmacology.
Effects across the members diverge sharply. Nitrous oxide produces brief euphoric dissociation when inhaled and serves clinically as an inhalational anaesthetic and analgesic;[1] lithium produces no acute altered state and is used as a mood stabiliser whose therapeutic effect emerges over weeks of consistent dosing.[2] Recreational use is essentially confined to nitrous oxide; lithium remains a prescription psychiatric medication.
Pharmacology
The members of this class do not share a pharmacological mechanism. Membership is defined structurally, and the two converge only on the physical fact that each acts on the central nervous system without an organic ligand — one as a dissolved gas, the other as a small cation.
| Member | Primary mechanism | Secondary targets |
|---|---|---|
| Nitrous oxide | Non-competitive NMDA glutamate receptor antagonism via open-channel block | Two-pore-domain K+ channels; endogenous opioid peptide release; weak GABAA activity[1] |
| Lithium | Inhibition of glycogen synthase kinase-3 (GSK-3) | Inositol monophosphatase inhibition; BDNF–TrkB upregulation; serotonergic and dopaminergic modulation[3] |
For nitrous oxide, NMDA antagonism is the dominant action and accounts for most of its anaesthetic and dissociative effects; activation of two-pore-domain potassium channels hyperpolarises neurons, and release of endogenous opioids drives descending analgesic pathways.[4][1] Lithium acts as a small cation that competes with magnesium and substitutes for sodium and potassium across multiple targets; its best-supported therapeutic mechanism is GSK-3 inhibition, with additional contributions from inositol depletion, BDNF–TrkB signalling, and monoamine neurotransmission.[5][3]
Because the mechanisms diverge entirely, this class — unlike a functional or target-defined grouping — has no common endpoint to which its members converge. Pharmacological discussion of either member must be conducted at the member level.
Substances
The brief lists two members, each illustrating a different corner of the inorganic-molecule space.
| Member | Chemical form | Role / distinctive feature |
|---|---|---|
| Nitrous oxide | Inorganic gas (N2O) | Inhaled anaesthetic and analgesic since the 19th century; brief recreational dissociative euphoria; among the most prevalent inhaled recreational substances in Europe[6] |
| Lithium | Alkali-metal cation (Li+), given as carbonate or citrate salt | First-line maintenance treatment for bipolar disorder; antidepressant augmentation; anti-suicidal effect over long-term use[7] |
These members differ in essentially every dimension except their inorganic structure: gas versus ion, recreational versus therapeutic, seconds-to-minutes versus weeks-to-months. The pairing makes the class useful as a structural boundary marker, not as a guide to shared behaviour.
Subjective Effects
The class has no shared effect profile. The two members produce qualitatively different experiences and operate on different timescales, so a single low-to-high exposure trajectory does not describe both.
| Member | Time course | Effect profile |
|---|---|---|
| Nitrous oxide | Onset within seconds; full recovery within minutes of stopping inhalation[6] | Euphoria, analgesia, anxiolysis, auditory distortion, dissociation, and impaired coordination; at anaesthetic concentrations, loss of consciousness |
| Lithium | Therapeutic mood effects emerge over weeks of consistent dosing[2] | No acute altered state; reduced amplitude of mood episodes; mild cognitive slowing reported as a common side effect; at supratherapeutic levels, tremor, ataxia, and confusion |
The same axis — divergence — drives the safety logic in the next section. Because nothing about one member's effects predicts the other's, every effect claim on this class is really a claim about a specific member, and the page treats them separately.
Safety
Risk profile
The two members of this class carry entirely different acute dangers, and a class-wide warning is therefore split. For nitrous oxide: the defining acute risk is asphyxiation — inhalation from a bag, mask, or sealed space displaces oxygen and can cause fatal hypoxia, and direct inhalation from a pressurised tank can cause frostbite to the lips, throat, and airway. For lithium: the defining risk is a narrow therapeutic window, so that dehydration, sodium depletion, or interacting medications can push serum levels into neurotoxic range.Surveillance in the United States has documented sharply rising poison-centre contacts, emergency-department visits, and emergency-medical-service responses related to recreational nitrous oxide through 2023.[8] Repeated heavy use carries a distinct, slower-developing harm: nitrous oxide irreversibly oxidises the cobalt atom of vitamin B12, inactivating methionine synthase and producing functional B12 deficiency, peripheral neuropathy, and subacute combined degeneration of the spinal cord.[9][6] Because B12 is inactivated rather than depleted, serum B12 can read normal — plasma homocysteine and methylmalonic acid are the more sensitive markers.
Lithium toxicity is, by contrast, a complication of long-term therapy rather than of a single exposure. Concurrent NSAIDs, certain diuretics, sodium depletion, and reduced renal clearance can all precipitate it; chronic exposure is independently associated with nephrogenic diabetes insipidus, hypothyroidism, and declining renal function over years.[2] Severe neurotoxicity can leave persistent cerebellar and cognitive deficits (the Syndrome of Irreversible Lithium-Effectuated Neurotoxicity).
Combinations also differ. Nitrous oxide potentiates other CNS depressants, including opioids, benzodiazepines, and alcohol — a property exploited in clinical anaesthesia and a hazard recreationally. Lithium's clinically important interactions are predominantly pharmacokinetic and renal, not depressant-additive.
Tolerance & dependence
Tolerance to nitrous oxide's euphoric and dissociative effects has been reported with frequent use, though systematic data remain limited.[10] A 2024 systematic evaluation found consistent evidence that heavy users meet several DSM-5 substance-use-disorder criteria — craving, impaired control, continued use despite harm, and social consequences — and concluded that nitrous oxide should be treated as potentially addictive, even though a classical physical withdrawal syndrome has not been characterised.[10]
Lithium does not produce tolerance in the recreational sense and is not habit-forming; patients do not require dose escalation to maintain effect. Abrupt discontinuation, however, carries a clinically significant risk of rapid relapse into mania or hypomania that appears to exceed the natural episode frequency, and a gradual taper over months is the established approach.[2]
Recovery
Both harms in this class have established cessation pathways. For nitrous-oxide-related neurological injury, permanent cessation combined with high-dose intramuscular vitamin B12 supplementation is the primary intervention; recovery is possible but can be slow and incomplete once spinal cord demyelination is established, so earlier presentation matters.[9]For lithium, stopping should be planned with a clinician and tapered over months to limit rebound relapse, and any sign of toxicity — coarse tremor, confusion, ataxia — is a reason to seek urgent medical evaluation. In both cases, the right next step is to talk to a clinician rather than to act alone.
Recovery resources, crisis lines, and support pathways → View all
references
- [1] ^abcSanders RD, Weimann J, Maze M (2008) Biologic effects of nitrous oxide: a mechanistic and toxicologic review — Anesthesiology doi:10.1097/aln.0b013e3181870a17
- [2] ^abcdOruch, R. and Elderbi, M.A. and Khattab, H.A. and Pryme, I.F. and Lund, A. (2014) Lithium: a review of pharmacology, clinical uses, and toxicity — European Journal of Pharmacology doi:10.1016/j.ejphar.2014.06.042
- [3] ^abMalhi, G.S. and Outhred, T. (2016) Therapeutic Mechanisms of Lithium in Bipolar Disorder: Recent Advances and Current Understanding — CNS Drugs doi:10.1007/s40263-016-0380-1
- [4] ^Jevtović-Todorović, V. and Todorović, S.M. and Mennerick, S. and Powell, S. and Dikranian, K. and Benshoff, N. and Zorumski, C.F. and Olney, J.W. (1998) Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin — Nature Medicine doi:10.1038/nm0498-460
- [5] ^Malhi, G.S. and Tanious, M. and Das, P. and Coulston, C.M. and Berk, M. (2013) Potential mechanisms of action of lithium in bipolar disorder. Current understanding — CNS Drugs doi:10.1007/s40263-013-0039-0
- [6] ^abcGernez É et al. (2023) Nitrous Oxide Abuse: Clinical Outcomes, Pharmacology, Pharmacokinetics, Toxicity and Impact on Metabolism — Toxics doi:10.3390/toxics11120962